4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (Nasdaq: FDMT), a late-stage biotechnology company, has granted 4,600 Restricted Stock Units (RSUs) to one new non-executive employee on July 8, 2025. The RSUs were awarded under the Company's 2025 Employment Inducement Award Plan, which was established in February 2025 in accordance with Nasdaq Global Market Rule 5635(c)(4) to incentivize new employee recruitment.
4D Molecular Therapeutics (Nasdaq: FDMT), un'azienda biotecnologica in fase avanzata, ha assegnato 4.600 Unit脿 Azionarie Vincolate (RSU) a un nuovo dipendente non esecutivo il 8 luglio 2025. Le RSU sono state concesse nell'ambito del Piano di Incentivi per l'Assunzione 2025 della Societ脿, istituito a febbraio 2025 in conformit脿 con la Regola 5635(c)(4) del Nasdaq Global Market, al fine di favorire il reclutamento di nuovi dipendenti.
4D Molecular Therapeutics (Nasdaq: FDMT), una empresa biotecnol贸gica en etapa avanzada, ha otorgado 4,600 Unidades de Acciones Restringidas (RSU) a un nuevo empleado no ejecutivo el 8 de julio de 2025. Las RSU fueron concedidas bajo el Plan de Incentivos por Contrataci贸n 2025 de la Compa帽铆a, establecido en febrero de 2025 conforme a la Regla 5635(c)(4) del Nasdaq Global Market para fomentar la contrataci贸n de nuevos empleados.
4D Molecular Therapeutics (雮橃姢雼�: FDMT)電� 頉勱赴 雼硠 氚旍澊鞓ろ厡韥� 旮办梾鞙茧靹� 2025雲� 7鞗� 8鞚� 鞁犼窚 牍勳瀯鞗� 歆侅洂 頃� 氇呾棎瓴� 4,600 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐枅鞀惦媹雼�. 鞚� RSU電� 鞁犼窚 歆侅洂 毂勳毄鞚� 鞛ル牑頃橁赴 鞙勴暣 2025雲� 2鞗� 雮橃姢雼� 旮�搿滊矊 毵堨紦 攴滌箼 5635(c)(4)鞐� 霐半澕 靹る霅� 須岇偓鞚� 2025 瓿犾毄 鞙犾澑 氤挫儊 瓿勴殟鞐� 霐半澕 靾橃棳霅橃棃鞀惦媹雼�.
4D Molecular Therapeutics (Nasdaq : FDMT), une entreprise biotechnologique en phase avanc茅e, a attribu茅 4 600 unit茅s d鈥檃ctions restreintes (RSU) 脿 un nouvel employ茅 non cadre le 8 juillet 2025. Les RSU ont 茅t茅 accord茅es dans le cadre du Plan d鈥檌ncitation 脿 l鈥檈mploi 2025 de la soci茅t茅, 茅tabli en f茅vrier 2025 conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq Global Market, afin de stimuler le recrutement de nouveaux employ茅s.
4D Molecular Therapeutics (Nasdaq: FDMT), ein Biotechnologieunternehmen in der Sp盲tphase, hat am 8. Juli 2025 einem neuen nicht gesch盲ftsf眉hrenden Mitarbeiter 4.600 Restricted Stock Units (RSUs) gew盲hrt. Die RSUs wurden im Rahmen des 2025 Employment Inducement Award Plans des Unternehmens vergeben, der im Februar 2025 gem盲脽 der Nasdaq Global Market Regel 5635(c)(4) eingerichtet wurde, um die Rekrutierung neuer Mitarbeiter zu f枚rdern.
- None.
- None.
EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 8, 2025, the compensation committee of the Company鈥檚 board of directors granted one new non-executive employee 4,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company鈥檚 2025 Employment Inducement Award Plan, which was approved by the Company鈥檚 board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company鈥檚 lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company鈥檚 lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company鈥檚 second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics鈩�, 4DMT鈩�, Therapeutic Vector Evolution鈩�, and the 4DMT logo are trademarks of 4DMT.
All of the Company鈥檚 product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company鈥檚 product candidates for the therapeutic uses for which they are being studied.
Learn more at and follow us on .
Contacts: Media: Jenn Gordon dna Communications [email protected] Investors: Julian Pei Head of Investor Relations and Corporate Finance [email protected]
FAQ
What type of stock compensation did 4D Molecular Therapeutics (FDMT) grant in July 2025?
When was 4DMT's Employment Inducement Award Plan approved?
What is the purpose of FDMT's Employment Inducement Award Plan?
How many employees received RSU grants from 4DMT in July 2025?
